Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]

Provided herein are pharmaceutical compositions, and in particular, oral pharmaceutical compositions, and methods of using these pharmaceutical compositions in the treatment of viral infections, including hepatitis C virus infections in hosts in need thereof. In certain embodiments, pharmaceutical compositions of 2′-C-methyl-guanosine, 5′-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl N-(phenylmethyl)phosphoramidate] are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. 2) The oral pharmaceutical composition of claim 1 , wherein the duration is 18 months.3) The oral pharmaceutical composition of claim 1 , wherein the duration is 24 months.4) The oral pharmaceutical composition of claim 1 , wherein when stored at 25° C. and 60% relative humidity for a duration of time of at least 12 months claim 1 , the composition comprises not more than 13 μg of ethylene sulfide per each gram of compound 1 in the composition.5) The oral pharmaceutical composition of claim 4 , wherein when stored at 25° C. and 60% relative humidity for a duration of time of at least 12 months claim 4 , the composition comprises not more than 10 μg of ethylene sulfide per each gram of compound 1 in the composition.6) The oral pharmaceutical composition of claim 5 , wherein when stored at 25° C. and 60% relative humidity for a duration of time of at least 12 months claim 5 , the composition comprises not more than 8 μg of ethylene sulfide per each gram of compound 1 in the composition.7) The oral pharmaceutical composition of claim 6 , wherein when stored at 25° C. and 60% relative humidity for a duration of time of at least 12 months claim 6 , the composition comprises not more than 5 μg of ethylene sulfide per each gram of compound 1 in the composition.8) The solid oral pharmaceutical composition of claim 1 , wherein the oral pharmaceutical composition is a solid oral pharmaceutical composition.9) The solid oral ...

3',5'-CYCLIC PHOSPHORAMIDATE PRODRUGS FOR HCV INFECTION

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. 2. The compound of wherein each Z is independently a carboxylene-substituted alkyl claim 1 , a cycloalkyl-substituted alkyl claim 1 , or both.3. (canceled)4. The compound of wherein:{'sub': p', '3', 'p', '3', 'p, 'each Z is -LC(O)O(L)CR, -LOC(O)(L)CR, or -LC(O)O(L)Cy;'}each L is independently alkylene, or substituted alkylene;each Cy is independently cycloalkyl or substituted cycloalkyl; andeach p is independently 0 or 1.5. The compound of claim 4 , wherein each L is independently C-Calkylene claim 4 , C-Cor C-Csubstituted alkylene.6. The compound of claim 4 , wherein each Cy is independently C-Ccycloalkyl or C-Csubstituted cycloalkyl.7. (canceled)8. (canceled)9. (canceled)10. The compound of wherein X is C-Calkoxyl.11. The compound of wherein X is hydroxyl.12. The compound of wherein X is hydrogen.13. The compound of wherein Y is fluoro.14. The compound of wherein Y is acetoxyl.15. The compound of wherein Y is hydroxyl.18. The compound of wherein:{'sub': p', '3', 'p', '3, 'each Z is independently -L-S—S-(L)CRor -LSC(O)(L)CR;'}each L is independently alkylene, or substituted alkylene; andeach p is independently 0 or 1.19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier or diluent.24. The pharmaceutical composition of claim 23 , wherein the composition is an oral formulation.25. A method for the treatment of a host infected with a hepatitis C virus claim 1 , comprising the administration of an effective treatment amount of a compound of .26. The method of claim 25 , wherein the host is a human.27. The method of claim 25 , wherein the ...

D-AMINO ACID COMPOUNDS FOR LIVER DISEASE

Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. 2. The compound of wherein each Ris independently alkyl claim 1 , cycloalkyl claim 1 , heterocyclylalkyl claim 1 , aryl claim 1 , heteroaryl claim 1 , arylalkyl claim 1 , heteroarylalkyl claim 1 , alkylcarbonylthioalkyl claim 1 , alkoxycarbonylalkyl claim 1 , arylalkoxycarbonylalkyl claim 1 , alkylcarbonylalkoxy(arylalkyl) claim 1 , (alkoxycarbonyl)(alkoxycarbonylamino)alkyl claim 1 , cycloalkylcarbonylalkoxyl claim 1 , alkoxycarbonylaminoalkylcarbonylthioalkyl claim 1 , hydroxylalkylcarbonylthioalkyl claim 1 , aminoalkylcarbonylalkoxycarbonylthioalkyl claim 1 , or hydantoinylalkyl.4. The compound of wherein Rand Rare H.510-. (canceled)11. The compound of wherein W is O claim 1 , and Ris Cl claim 1 , F or OH.12. (canceled)15. The compound of wherein Ris alkylamino.18. The Rcompound of .19. The Scompound of .20. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier or diluent.21. The pharmaceutical composition of claim 20 , wherein the composition is an oral formulation.22. A method for the treatment of a host infected with a hepatitis C virus claim 1 , comprising the administration of an effective treatment amount of a compound of .23. The method of claim 22 , wherein the host is a human.24. The method of claim 22 , wherein the administration directs a substantial amount of the compound claim 22 , or pharmaceutically acceptable salt or stereoisomer thereof claim 22 , to a liver of the host.25. The method of claim 22 , wherein the compound or composition is administered in combination or alternation with a second anti-viral agent selected from the group consisting of an interferon claim 22 , a ...

D-AMINO ACID COMPOUNDS FOR LIVER DISEASE

Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. 12-. (canceled)428-. (canceled)46. The pharmaceutical composition of claim 45 , wherein said composition provides a therapeutically effective amount of said compound for treating a human infected with HCV.53. The pharmaceutical composition of claim 51 , wherein said compound is a designated enantiomer claim 51 , and said composition is substantially free of other stereoisomers of said compound.54. The pharmaceutical composition of claim 52 , wherein said compound is a designated enantiomer claim 52 , and said composition is substantially free of other stereoisomers of said compound. Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of liver diseases and conditions, including viral infections such as hepatitis C virus infections in hosts in need thereof. In certain embodiments, D-amino acids linked to therapeutic nucleoside analogs are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.The hepatitis C virus (HCV) is the leading cause of chronic liver disease worldwide. (Boyer, N. et al., 32:98-112, 2000). HCV causes a slow growing viral infection and is the major cause of cirrhosis and hepatocellular carcinoma (Di Besceglie, A. M. and Bacon, B. R., , October: 80-85, 1999; Boyer, N. et al., 32:98-112, 2000). It is estimated there are about 130-170 million people with chronic hepatitis C virus infection, and there are about 350,000 deaths from hepatitis C-related liver diseases each year (Hepatitis C Fact Sheet, 164, June 2011). Cirrhosis caused by chronic hepatitis C infection accounts for 8,000-12,000 deaths per year in the United States, and HCV ...

2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′,4′-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2′,4′-bridged nucleosides are of Formula 3001: 3. The compound of claim 2 , wherein each B is independently guanine claim 2 , 2′-ethoxylguanine claim 2 , cytosine claim 2 , adenine claim 2 , 2′ claim 2 ,6′-diaminopurine claim 2 , thymine claim 2 , uracil claim 2 , or 5′-fluorouracil.5. The compound of claim 4 , wherein each Ris independently branched hydroxyalkyl.6. The compound of claim 4 , wherein each Ris —C(CH)CHOH.8. (canceled)10. (canceled)12. (canceled)14. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier or diluent.15. The pharmaceutical composition of claim 14 , wherein the composition is an oral formulation.16. A method for the treatment of a host infected with a hepatitis C virus claim 1 , comprising the administration of an effective treatment amount of the compound of .17. The method of claim 16 , wherein the host is a human.18. The method of claim 16 , wherein the administration directs a substantial amount of the compound claim 16 , or pharmaceutically acceptable salt or stereoisomer thereof claim 16 , to a liver of the host.19. The method of claim 16 , wherein the compound is administered in combination or alternation with a second anti-viral agent selected from the group consisting of an interferon claim 16 , a nucleotide analogue claim 16 , a polymerase inhibitor claim 16 , an NS3 protease inhibitor claim 16 , an NS5A inhibitor claim 16 , an entry inhibitor claim 16 , a non ...

Solid forms of a flaviviridae virus inhibitor compound and salts thereof

Provided herein are crystalline and salt forms of methyl N-{(1R)-2-[(2S)-2-{5-[4-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-yl]-3H-benzimidazol-5-yl}thieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl} carbamate, a Flaviviridae, including hepatitis C, virus inhibitor, pharmaceutical compositions comprising the compound, and processes of preparation thereof. Also provided are methods of its use for the treatment of a Flaviviridae, including HCV, infection in a subject in need thereof.

SOLID PRODRUG FORMS OF 2'-CHLORO-2'-METHYL URIDINE FOR HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are solid forms of Compound I: (Compound I) 2. Compound I of where the compound is in substantially pure crystalline form.3. Compound I of claim 1 , wherein said compound is Form I claim 1 , and said Form I is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 6.8 claim 1 , about 15.7 claim 1 , and about 18.5.4. Compound I of claim 2 , wherein said Form I is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 6.8 claim 2 , about 15.7 claim 2 , about 18.5 claim 2 , about claim 2 , 18.0 about 13.6 claim 2 , and about 10.8.5. Compound I of claim 3 , wherein said Form I is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 6.8 claim 3 , about 15.7 claim 3 , about 18.5 claim 3 , about 10.8 claim 3 , about 13.6 claim 3 , about 18.0 claim 3 , about 7.3 claim 3 , about 8.2 claim 3 , and about 19.3.6. Compound I of claim 4 , wherein said Form I is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 6.8 claim 4 , about 15.7 claim 4 , about 18.5 claim 4 , about 10.8 claim 4 , about 13.6 claim 4 , about 18.0 claim 4 , about 7.3 claim 4 , about 8.2 claim 4 , about 19.3 claim 4 , about 16.8 claim 4 , about 19.7 claim 4 , about 21.4 claim 4 , about 21.8 claim 4 , about 23.6 claim 4 , about 24.4 claim 4 , about 24.8 and about 26.5.7. Compound I of wherein said compound is Form I claim 1 , and said From I is characterized by ...

2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-chloro nucleosides according to Formula 2001: 12-. (canceled)441-. (canceled)49. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt claim 3 , solvate claim 3 , tautomeric form or polymorphic form thereof; and a pharmaceutically acceptable carrier.54. The pharmaceutical composition according to claim 53 , wherein said compound is a designated enantiomer claim 53 , and said composition is substantially free of other stereoisomers of said compound.57. The pharmaceutical composition according to claim 56 , wherein said compound is a designated enantiomer claim 56 , and said composition is substantially free of other stereoisomers of said compound.58. A method for the treatment of a human infected with a hepatitis C virus claim 3 , comprising the administration to said human an effective amount of a compound according to or a pharmaceutically acceptable salt claim 3 , solvate claim 3 , tautomeric form or polymorphic form thereof.65. The method of claim 58 , wherein the compound is administered in combination with a second anti-viral agent selected from the group consisting of an interferon claim 58 , a nucleotide analogue claim 58 , a polymerase inhibitor claim 58 , an NS3 protease inhibitor claim 58 , an NS5A inhibitor claim 58 , an entry inhibitor claim 58 , a non-nucleoside polymerase inhibitor claim 58 , a cyclosporine immune inhibitor claim 58 , an NS4A antagonist claim 58 , an NS4B-RNA binding inhibitor claim 58 , a locked nucleic acid mRNA inhibitor claim 58 , a cyclophilin inhibitor claim 58 , and combinations thereof.67. The method of claim 66 , wherein said second anti-viral ...

4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: 4. The compound of claim 1 , wherein W is O.6. The compound of claim 5 , wherein Ris branched hydroxyalkyl.7. (canceled)11. The compound of claim 1 , wherein Y is an N-linked or O-linked amino acid residue or an N-linked or O-linked residue of an amino acid derivative.13. The compound of claim 1 , wherein Ris hydroxyl and Ris hydrogen or methyl.14. (canceled)1617-. (canceled)18. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier claim 1 , or diluent.19. The pharmaceutical composition of claim 18 , wherein the composition is an oral formulation.20. A method for the treatment of a human host infected with a hepatitis C virus comprising administering an effective amount of a compound of .21. (canceled)22. The method of claim 20 , wherein the administration comprises directing the compound claim 20 , or pharmaceutically acceptable salt or stereoisomer thereof claim 20 , to a liver of the host.23. The method of claim 20 , wherein the compound is administered in combination or alternation with a second anti-viral agent selected from an interferon claim 20 , a nucleotide analogue claim 20 , a polymerase inhibitor claim 20 , an NS3 protease inhibitor claim 20 , an NS5A inhibitor claim 20 , an entry inhibitor claim 20 , a non-nucleoside polymerase inhibitor claim 20 , a cyclosporine immune inhibitor claim 20 , an NS4A antagonist claim 20 , an NS4B-RNA binding inhibitor claim 20 , a locked nucleic acid mRNA inhibitor claim 20 , a cyclophilin inhibitor claim 20 , or combination thereof.24. The method of claim 23 , wherein the second anti- ...

AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-cyano, azido or amino nucleosides according to Formula 1001 or 2001: 11. (canceled)12. The compound of claim 1 , wherein Ris hydrogen claim 1 , methyl claim 1 , or halo.14. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier claim 1 , or diluent.15. The pharmaceutical composition of claim 14 , wherein the composition is an oral formulation.16. A method for the treatment of a host infected with a hepatitis C virus claim 1 , comprising the administering of an effective treatment amount of a compound of .17. The method of claim 16 , wherein the host is a human.18. The method of claim 16 , wherein the administering directs a substantial amount of the compound claim 16 , or pharmaceutically acceptable salt or stereoisomer thereof claim 16 , to a liver of the host.19. The method of claim 16 , wherein the compound or composition is administered in combination or alternation with a second anti-viral agent claim 16 , wherein the second antiviral agent is an interferon claim 16 , a nucleotide analogue claim 16 , a polymerase inhibitor claim 16 , an NS3 protease inhibitor claim 16 , an NS5A inhibitor claim 16 , an entry inhibitor claim 16 , a non-nucleoside polymerase inhibitor claim 16 , a cyclosporine immune inhibitor claim 16 , an NS4A antagonist claim 16 , an NS4B-RNA binding inhibitor claim 16 , a locked nucleic acid mRNA inhibitor claim 16 , a cyclophilin inhibitor claim 16 , or a combination thereof.20. (canceled)21. (canceled) Provided herein are compounds, methods, and pharmaceutical compositions for use in treatment of viral infections, including hepatitis ...

3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-deoxy nucleoside compounds according to Formula 3001a or 3001b: 3. The compound of claim 1 , wherein W is O.5. The compound of claim 4 , wherein Ris branched hydroxyalkyl.6. The compound of claim 4 , wherein Ris —C(CH)CHOH.12. (canceled)14. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier claim 1 , or diluent.15. The pharmaceutical composition of claim 14 , wherein the composition is an oral formulation.16. A method for the treatment of a host infected with a hepatitis C virus claim 1 , comprising the administration of an effective treatment amount of a compound of .17. The method of claim 16 , wherein the host is a human.18. The method of claim 16 , wherein the administration directs a substantial amount of the compound claim 16 , or pharmaceutically acceptable salt or stereoisomer thereof claim 16 , to a liver of the host.19. The method of claim 16 , wherein the compound is administered in combination or alternation with a second anti-viral agent claim 16 , wherein the second anti-viral agent is an interferon claim 16 , a nucleotide analogue claim 16 , a polymerase inhibitor claim 16 , an NS3 protease inhibitor claim 16 , an NS5A inhibitor claim 16 , an entry inhibitor claim 16 , a non-nucleoside polymerase inhibitor claim 16 , a cyclosporine immune inhibitor claim 16 , an NS4A antagonist claim 16 , an NS4B-RNA binding inhibitor claim 16 , a locked nucleic acid mRNA inhibitor claim 16 , a cyclophilin inhibitor claim 16 , or a combination thereof.20. The method of claim 19 , wherein the second anti-viral agent is IDX-719 claim 19 , TMC435 claim 19 , ...

THIOPHOSPHATE NUCLEOSIDES FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: 10. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier claim 1 , or diluent.11. The pharmaceutical composition of claim 10 , wherein the composition is an oral formulation.12. A method for the treatment of a host infected with a hepatitis C virus claim 1 , comprising the administration of an effective treatment amount of a compound of .13. The method of claim 12 , wherein the host is a human.14. The method of claim 12 , wherein the administration directs a substantial amount of the compound claim 12 , or pharmaceutically acceptable salt or stereoisomer thereof claim 12 , to a liver of the host.15. The method of claim 12 , wherein the compound is administered in combination or alternation with a second anti-viral agent claim 12 , wherein the second anti-viral agent is an interferon claim 12 , a nucleotide analogue claim 12 , a polymerase inhibitor claim 12 , an NS3 protease inhibitor claim 12 , an NS5A inhibitor claim 12 , an entry inhibitor claim 12 , a non-nucleoside polymerase inhibitor claim 12 , a cyclosporine immune inhibitor claim 12 , an NS4A antagonist claim 12 , an NS4B-RNA binding inhibitor claim 12 , a locked nucleic acid mRNA inhibitor claim 12 , a cyclophilin inhibitor claim 12 , or combination thereof.16. The method of claim 15 , wherein the second anti-viral agent is IDX-719 claim 15 , TMC435 claim 15 , PSI-7977 claim 15 , telaprevir claim 15 , boceprevir claim 15 , interferon alfacon-1 claim 15 , interferon alfa-2b claim 15 , pegylated interferon alpha 2a claim 15 , pegylated interferon alpha 2b claim 15 , ribavirin claim 15 , and combinations thereof.17. The method of claim 15 , wherein the second anti-viral agent is IDX-719 claim 15 , TMC435 claim 15 , PSI-7977 claim 15 , telaprevir claim ...

4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4′-OR nucleosides of Formula I: 2. The compound of claim 1 , wherein the nucleobase is selected from purine claim 1 , pyrimidine claim 1 , adenine claim 1 , N-alkylpurines claim 1 , N-acylpurines claim 1 , N-benzylpurine claim 1 , N-halopurine claim 1 , N-vinylpurine claim 1 , N-acetylenic purine claim 1 , N-acyl purine claim 1 , N-hydroxyalkyl purine claim 1 , N-alkylaminopurine claim 1 , N-thioalkyl purine claim 1 , N-alkylpurines claim 1 , N-alkyl-6-thiopurines claim 1 , thymine claim 1 , cytosine claim 1 , 5-fluorocytosine claim 1 , 5-methylcytosine claim 1 , 6-azapyrimidine claim 1 , including 6-azacytosine claim 1 , 2- and/or 4-mercaptopyrmidine claim 1 , uracil claim 1 , 5-halouracil claim 1 , 5-fluorouracil claim 1 , C-alkylpyrimidines claim 1 , C-benzylpyrimidines claim 1 , C-halopyrimidines claim 1 , C-vinylpyrimidine claim 1 , C-acetylenic pyrimidine claim 1 , C-acyl pyrimidine claim 1 , C-hydroxyalkyl purine claim 1 , C-amidopyrimidine claim 1 , C-cyanopyrimidine claim 1 , C-iodopyrimidine claim 1 , C-iodo-pyrimidine claim 1 , C—Br-vinyl pyrimidine claim 1 , C—Br-vinyl pyrimidine claim 1 , C-nitropyrimidine claim 1 , C-amino-pyrimidine claim 1 , N-alkylpurines claim 1 , N-alkyl-6-thiopurines claim 1 , 5-azacytidine claim 1 , 5-azauracil claim 1 , triazolopyridine claim 1 , imidazolopyridine claim 1 , pyrrolopyrimidine claim 1 , pyrazolopyrimidine claim 1 , guanine claim 1 , hypoxanthine claim 1 , 7-deazaguanine claim 1 , 7-deazaadenine claim 1 , 2 claim 1 ,6-diaminopurine claim 1 , 6-chloropurine claim 1 , 7-fluoro-7-deazaguanine claim 1 , 7-fluoro-7-deazaadenine claim 1 , 2-amino-6-chloropurine claim 1 , 6- ...

2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV

Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2′,4′-fluoro nucleosides according to Formula 1001: 132512. The compound of any of - or - claims 1 , wherein Ris fluoro or hydroxyl.1615. A pharmaceutical composition comprising the compound of any one of - and a pharmaceutically acceptable excipient claims 1 , carrier claims 1 , or diluent.17. The pharmaceutical composition of claim 16 , wherein the composition is an oral formulation.1817. A method for the treatment of a host infected with a virus comprising administering to the host an effective amount of a compound or composition of any one of -.19. The method of claim 18 , wherein the host is a human.20. The method of or claim 18 , wherein the virus is a hepatitis C virus.2120. The method of any of - comprising directing a substantial amount of the compound claims 18 , or pharmaceutically acceptable salt or stereoisomer thereof claims 18 , to a liver of the host.2221. The method of any of - comprising administering a second anti-viral agent in combination or alternation with the compound or the composition claims 18 , wherein the second anti-viral agent is an interferon claims 18 , a nucleotide analogue claims 18 , a polymerase inhibitor claims 18 , an NS3 protease inhibitor claims 18 , an NS5A inhibitor claims 18 , an entry inhibitor claims 18 , a non-nucleoside polymerase inhibitor claims 18 , a cyclosporine immune inhibitor claims 18 , an NS4A antagonist claims 18 , an NS4B-RNA binding inhibitor claims 18 , a locked nucleic acid mRNA inhibitor claims 18 , a cyclophilin inhibitor claims 18 , or a combination thereof.23. The method of claim 22 , wherein the second anti-viral agent is samatasvir claim 22 , simeprevir claim 22 , sofosbuvir claim 22 , telaprevir claim 22 , boceprevir claim 22 , interferon alfacon-1 claim 22 , interferon alfa ...

D-AMINO ACID COMPOUNDS FOR LIVER DISEASE

Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. 12-. (canceled)417-. (canceled)185. The Rcompound of claim .195. The Scompound of claim .2028-. (canceled)29. The compound of wherein{'sup': '1', 'Y is —OR;'}{'sup': '1', 'Ris phenyl; and'}{'sup': 'b2', 'Ris —OH or —F.'}32. The nucleoside composition of wherein{'sup': '1', 'Y is —OR;'}{'sup': 'd', 'Ris —H;'}{'sup': '1', 'Ris phenyl; and'}{'sup': 'b2', 'Ris —OH or —F.'}33. The nucleoside composition of claim 32 , wherein the composition provides a therapeutically effective amount of the compound for treating a human infected with HCV.35. The pharmaceutical composition of wherein{'sup': '1', 'Y is —OR;'}{'sup': '1', 'Ris phenyl; and'}{'sup': 'b2', 'Ris —F or —OH.'}36. The pharmaceutical composition of claim 35 , wherein the pharmaceutical composition provides a therapeutically effective amount of the compound for treating a human infected with HCV.38. The method of claim 37 , wherein{'sup': '1', 'Y is —OR;'}{'sup': '1', 'Ris phenyl; and'}{'sup': 'b2', 'Ris —OH or —F.'}39. The method of claim 37 , wherein the compound is administered in combination or alternation with a second anti-viral agent selected from the group consisting of an interferon claim 37 , a nucleotide analogue claim 37 , a polymerase inhibitor claim 37 , an NS3 protease inhibitor claim 37 , an NS5A inhibitor claim 37 , an entry inhibitor claim 37 , a non-nucleoside polymerase inhibitor claim 37 , a cyclosporine immune inhibitor claim 37 , an NS4A antagonist claim 37 , an NS4B-RNA binding inhibitor claim 37 , a locked nucleic acid mRNA inhibitor claim 37 , a cyclophilin inhibitor claim 37 , and combinations thereof.40. The method of claim 39 , wherein the second anti-viral agent is an HCV NS3 ...

D-ALANINE PHOSPHORAMIDE PRONUCLEOTIDES OF 2'-METHYL 2'-FLURO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-alanine phosphoramidate pronucleotides of 2′-methyl 2′-fluoro guanosine nucleoside which display remarkable efficacy and bioavailability for the treatment of for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; where W and R are as described herein. 3. The compound of claim 1 , wherein the alkoxyl is —OR′ claim 1 , wherein R′ is alkyl or cycloalkyl claim 1 , and wherein alkyl is Cto Calkyl claim 1 , and cycloalkyl is Cto Ccycloalkyl.4. The compound of claim 1 , wherein the alkoxyl is selected from the group consisting of methoxyl claim 1 , ethoxyl claim 1 , n-propoxyl claim 1 , isopropoxyl claim 1 , n-butoxyl claim 1 , tert-butoxyl claim 1 , sec-butoxyl claim 1 , n-pentoxyl claim 1 , n-hexoxyl claim 1 , and 1 claim 1 ,2-dimethylbutoxyl.5. The compound of claim 1 , wherein W is O and R is hydrogen claim 1 , hydroxyl or alkoxyl.6. The compound of claim 5 , wherein W is O and R is hydroxyl or alkoxyl.7. The compound of claim 6 , wherein W is O and R is hydroxyl claim 6 , methoxyl or ethoxyl.8. The compound of any of claim 7 , wherein W is O and R is ethoxyl.9. The compound of claim 1 , wherein W is S and R is hydrogen claim 1 , hydroxyl or alkoxyl.10. The compound of claim 9 , wherein W is S and R is hydroxyl or alkoxyl.11. The compound of claim 10 , wherein W is S and R is hydroxyl claim 10 , methoxyl or ethoxyl.12. The compound of claim 11 , wherein W is S and R is ethoxyl.14. A substantially pure compound of .15. A pharmaceutical composition comprising the compound of ...

Niraparib Salts

Novel salts of niraparib are provided. Also provided are pharmaceutical compositions comprising those salts, as well as methods and uses pertaining to the same. 1. A 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide salt selected from the group consisting of:2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (1R,3S)-(+)-camphorate;2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (1S,3R)-(−)-camphorate;2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (R)-(−)-mandelate; and2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (1S)-(+)-camsylate.2. The 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide salt according to claim 1 , wherein the salt is a crystalline form.3. The 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide salt according to claim 2 , wherein the salt is 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (1R claim 2 ,3S)-(+)-camphorate.4. The 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide salt according to claim 3 , wherein the 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (1R claim 3 ,3S)-(+)-camphorate crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three diffraction angles claim 3 , when measured using Cu K radiation claim 3 , selected from a group consisting of about 13.4 claim 3 , 15.2 claim 3 , 16.2 claim 3 , 17.5 claim 3 , 18.0 claim 3 , 20.0 claim 3 , 20.4 claim 3 , 21.6 claim 3 , and 24.0 degrees 2θ.56.-. (canceled)7. The 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide salt according to claim 2 , wherein the 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (1R claim 2 ,3S)-(+)-camphorate crystalline form is characterised by an X-ray powder diffraction (XRPD) pattern substantially in accordance with .8. The 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide salt according to claim 2 , wherein the salt is 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7- ...

CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, ZZ, Z, Z, V, W, X, Y, Ar, Rand Rare as described herein. 2. The compound of claim 1 , wherein:{'sup': 6', '6', '6', '6', '6', '6', '6', '6', '6', '6', '2', '2', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '6', '5', '6', '5', '5', '2', '2, 'the nucleobase is selected from the group consisting of purine, pyrimidine, adenine, N-alkylpurines, N-acylpurines, N-benzylpurine, N-halopurine, N-vinylpurine, N-acetylenic purine, N-acyl purine, N-hydroxyalkyl purine, N-alkylaminopurine, N-thioalkyl purine, N-alkylpurines, N-alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, 6-azacytosine, 2-mercaptopyrmidine, 4-mercaptopyrmidine, uracil, 5-halouracil, 5-fluorouracil, C-alkylpyrimidines, C-benzylpyrimidines, C-halopyrimidines, C-vinylpyrimidine, C-acetylenic pyrimidine, C-acyl pyrimidine, C-hydroxyalkyl purine, C-amidopyrimidine, C-cyanopyrimidine, C-iodopyrimidine, C-iodo-pyrimidine, C—Br-vinyl pyrimidine, C—Br-vinyl pyrimidine, C-nitropyrimidine, C-amino-pyrimidine, N-alkylpurines, N-alkyl-6-thiopurines, 5-azacytidine, 5-azauracil, triazolopyridine, imidazolopyridine, pyrrolopyrimidine, pyrrolotriazine, pyrazolopyrimidine, guanine, hypoxanthine, 7-deazaguanine, 7-fluoro-7-deazaguanine, 7-deazaadenine, 7-fluoro-7-deazaadenine, 2,6-diaminopurine, 2-amino-6-chloropurine, 6-ethoxypurine, 6-methoxylpurine, and 6-chloropurine;'}{'sub': 1-10', '1-10', '1-10', '1-10, 'each aryl is selected from the group consisting of phenyl, biphenyl, ...

Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]

Provided herein are stable pharmaceutical compositions comprising 2'-C-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-l-oxopropyl) thio]ethyl N-(phenylmethyl)phosphoramidate (also known s IDX-184), and in particular, oral pharmaceutical compositions such as tablets. The compositions are designed to avoid the formation of diethylene sulfide upon storage. Discosed are also methods of using these pharmaceutical compositions in the treatment of viral infections, including hepatitis C virus infections in hosts in need thereof.

D-amino acid compounds for liver disease

Provided herein are compounds comprising a D-amino acid, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

3',5'-cyclic phosphoramidate prodrugs for hcv infection

Provided herein are compounds of formula (I) compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. Formula (I) or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein: each X is independently alkoxyl, hydrogen, or hydroxyl; each Y is independently hydroxyl, acetoxyl, or fluoro; each Z is independently substituted alkyl; and each R is independently hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, or heteroaryl.

2',4'-bridged nucleosides for hcv infection

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2',4'-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2',4'-bridged nucleosides are of Formula 3001:(I) (3001); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, R A , R B , R C and R D are as described herein.

4'-fluoro nucleosides for the treatment of hcv

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula (1501): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, R A , R B , R C , L, M and Z are as described herein.

3'-deoxy nucleosides for the treatment of hcv

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'- deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base 1 and Base 2 are as provided herein.

Thiophosphate nucleosides for the treatment of hcv

Provided herein are compounds, compositions, and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001; where PD, Base, R A and R B are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

2',4'-fluoro nucleosides for the treatment of hcv

Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2',4'-fluoro nucleosides according to Formula 1001: (1001); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2',4'-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.

D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are of Formula AI or 1001 or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof.

D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; where W and R are as described herein.

4'-or nucleosides for the treatment of hcv

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4'-OR nucleosides of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z 1 , Z 2 , Z 3 , and Z 4 are as defined herein.

Solid forms of a flaviviridae virus inhibitor compound and salts thereof

Provided herein are crystalline and salt forms of methyl N -{(1R)-2-[(2S)-2-{5-[4-(6- {2- [(2S)- 1 - {(2S)-2- [(methoxycarbonyl)amino] -3 -methylbutanoyl} pyrro lidin-2-yl]-3 H - benzimidazol-5-y1}thieno[3,2- b ]thiophen-3-y1)phenyl]-1 H -imidazol-2-yl}pyrrolidin-1-y1]-2- oxo-1-phenylethyl} carbamate, a Flaviviridae, including hepatitis C, virus inhibitor, pharmaceutical compositions comprising the compound, and processes of preparation thereof. Also provided are methods of its use for the treatment of a Flaviviridae, including HCV, infection in a subject in need thereof.

Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv

Provided herein are compounds, compositions and methods for the treatment of Flavivirida e infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are solid forms of Compound I: (Compound I)

2’-chloro nucleoside analogs for hcv infection

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2’-chloro nucleosides according to Formula 2001: (2001); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

Thiophosphate nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, R A and R B are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

3′-deoxy nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base 1 and Base 2 are as provided herein.

2′,4′-fluoro nucleosides for the treatment of HCV

Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2′,4′-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, R A , and PD are as described herein. In certain embodiments, 2′,4′-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.

4′-or nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4′-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z 1 , Z 2 , Z 3 , and Z 4 are as defined herein.

3′,5′-cyclic phosphoramidate prodrugs for HCV infection

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

4′-fluoro nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, R A , R B , R C , L, M and Z are as described herein.

2′-chloro nucleoside analogs for HCV infection

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

D-amino acid compounds for liver disease

Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

2-chloro nucleoside analogs for hcv infection hcv 2-

D-AMINO ACID COMPOUNDS FOR LIVER DISEASE

En el presente documento se proporcionan compuestos, composiciones y métodos para el tratamiento de enfermedades y afecciones hepáticas, incluyendo infecciones por el VHC. En ciertas realizaciones, se desvelan compuestos y composiciones de derivados de nucleósido, que se pueden administrar solos o en combinación con otros agentes antivirales.

2 'ANALOGUES - NUCLEOSIDE CHLORINE FOR HCV INFECTIONS

En el presente documento se proporcionan compuestos, composiciones y métodos para el tratamiento de infecciones por Flaviviridae, incluyendo infecciones por HCV. En ciertas realizaciones, se desvelan compuestos y composiciones de derivados de nucleósidos, los que se pueden administrar solos o en combinación con otros agentes antivirales. En ciertas realizaciones, los compuestos son 2'-cloro nucleósidos de acuerdo con la Fórmula 2001: (2001); o una sal, solvato, forma estereoisomérica, forma tautomérica o forma polimórfica farmacéuticamente aceptable de los mismos, caracterizados por que B, Z y PD son tal como se describen en el presente documento.

4'-fluoro nucleosides for the treatment of hcv

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula (1501): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, R A , R B , R C , L, M and Z are as described herein.

D-amino acid compounds for liver disease

Provided herein are compounds comprising a D-amino acid, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

D-amino acid compounds for liver disease

2'-chloro nucleoside analogs for hcv infection

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-chloro nucleosides according to Formula 2001: (2001); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

3',5'-cyclic phosphoramidate prodrugs for hcv infection

2'-chloro nucleoside analogues for treating hepatitis c virus infection

La présente invention concerne des composés, des compositions et des méthodes pour le traitement d'infections par des flaviviridés, y compris des infections par le virus de l'hépatite c. Selon certains modes de réalisation, l'invention concerne des composés ou des compositions de dérivés de nucléosides qui peuvent être administrés soit seuls, soit en combinaison avec d'autres agents antiviraux. Dans certains modes de réalisation, les composés consistent en des nucléosides 2'-chloro répondant à la formule 2001 : (2001) ou en un sel, un solvate, une forme stéréo-isomère, une forme tautomère ou une forme polymorphe pharmaceutiquement acceptable associé, et dans laquelle b, z et pd sont tels que définis dans la description. The present invention provides compounds, compositions and methods for the treatment of flavivirideal infections, including hepatitis c virus infections. In some embodiments, the invention provides compounds or compositions of nucleoside derivatives that can be administered either alone or in combination with other antiviral agents. In some embodiments, the compounds are 2'-chloro nucleosides of formula 2001: (2001) or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, and wherein b, z and pd are as defined in the description.

D-amino acid compounds for liver disease.

En la presente se proveen compuestos que comprenden un D-aminoácido, composicones y métodos para el tratamimiento de enfermedad y condiciones hepáticas, que incluyen infecciones de HCV. En ciertas modalidades, se describen los compuestos y composiciones de derivados de nucleósidos, que pueden administrarse solos o en combinación con otros agentes antivirales.

D-amino acid compounds against liver diseases

L'invention concerne des composés contenant un acide d-aminé, ainsi que des compositions et des méthodes de traitement de maladies et affections hépatiques, notamment les infections à vhc. Dans certains modes de réalisation, l'invention concerne des composés et compositions de dérivés de nucléosides pouvant être administrés seuls ou associés à d'autres agents anti-viraux. Disclosed are compounds containing a d-amino acid, as well as compositions and methods for treating liver diseases and conditions, including vhc infections. In some embodiments, the invention provides nucleoside derivative compounds and compositions that can be administered alone or in combination with other anti-viral agents.

Crystalline forms of niraparib freebase

Crystalline niraparib freebase is provided. Also provided are pharmaceutical compositions comprising crystalline niraparib freebase, and methods and uses pertaining to the same.

2'-chloro nucleoside analogs for HCV infection.

Burada, HCV enfeksiyonları dahil olmak üzere, Flaviviridae enfeksiyonlarının tedavisi için bileşikler, bileşimler ve yöntemler sağlanmaktadır. Belirli uygulamalarda, nükleosit türevlerinin, tek başına veya diğer anti-viral ajanlarla kombinasyon halinde verilebilen bileşikleri ve bileşimleri açıklanmaktadır. Belirli uygulamalarda, bileşikler Formül 2001'e göre 2'-kloro nükleositler veya bunun farmakolojik olarak kabul edilen bir tuzu, solvatı, stereoizomerik form, totomerik formu veya polimorfik formu olup, burada B, Z ve PD, burada tarif edildiği gibidir.

4'-or nucleosides for the treatment of hcv

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4'-OR nucleosides of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z 1 , Z 2 , Z 3 , and Z 4 are as defined herein.

Niraparib salts

Use of adnf polypeptides for treating neurodegenerative diseases

This invention relates to the use of ADNF polypeptides in the treatment of neurodegenerative diseases based upon the identification of certain therapeutically effective pharmacokinetic parameters, dosing levels and formulations. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.